US2002049231A1PendingUtilityA1

Methods and compositions for inhibition of angiogenesis

56
Priority: Mar 1, 1993Filed: Sep 28, 2001Published: Apr 25, 2002
Est. expiryMar 1, 2013(expired)· nominal 20-yr term from priority
Inventors:Robert D'Amato
A61P 9/08A61P 35/04A61P 7/04A61P 7/06A61P 43/00A61P 9/10A61P 9/00A61P 37/02A61P 37/04A61P 3/10A61P 31/22A61P 27/00A61P 27/14A61P 31/12A61P 35/00A61P 33/02A61P 31/10A61P 27/10A61P 31/04A61P 27/06A61P 31/00A61P 29/00A61P 27/02A61P 35/02A61K 31/19C07D 403/02A61K 31/40A61K 31/44A61P 17/06A61P 19/00A61P 19/02A61K 31/4035A61P 1/00A61K 31/535A61P 17/02A61P 19/08A61P 17/00A61K 31/454A61K 31/445A61K 31/185A61K 31/33
56
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention comprises a group of compounds that effectively inhibit angiogenesis. More specifically, thalidomide and various related compounds such as thalidomide precursors, analogs, metabolites and hydrolysis products have been shown to inhibit angiogenesis. Importantly, these compounds can be administered orally.

Claims

exact text as granted — not AI-modified
1 . A composition for treating a disease in a human or animal comprising S(−)-3-aminothalidomide and having the following structure:  
       
         
           
           
               
               
           
         
       
     
     
         2 . A method of treating a disease in a human or animal comprising the step of administering to the human or animal with the disease a composition comprising S(−)-3-aminothalidomide and having the following structure:  
       
         
           
           
               
               
           
         
       
     
     
         3 . The method of  claim 2 , wherein the disease includes undesired angiogenesis associated with retinal/choroidal neovascularization.  
     
     
         4 . The method of  claim 2 , wherein the disease includes undesired angiogenesis associated with diabetic retinopathy.  
     
     
         5 . The method of  claim 2 , wherein the disease includes undesired angiogenesis associated with macular degeneration.  
     
     
         6 . The method of  claim 2 , wherein the disease includes undesired angiogenesis associated with corneal neovascularization.  
     
     
         7 . The method of  claim 2 , wherein the disease includes undesired angiogenesis that occurs in retinopathy of prematurity.  
     
     
         8 . The method of  claim 2 , wherein the disease includes undesired angiogenesis that occurs in corneal graft rejection.  
     
     
         9 . The method of  claim 2 , wherein the disease includes undesired angiogenesis that occurs in neovascular glaucoma.  
     
     
         10 . The method of  claim 2 , wherein the disease includes undesired angiogenesis that occurs in retrolental fibroplasia.  
     
     
         11 . The method of  claim 2 , wherein the disease includes undesired angiogenesis that occurs in epidemic keratoconjunctivitis.  
     
     
         12 . The method of  claim 2 , wherein the disease includes undesired angiogenesis that occurs due to Vitamin A deficiency.  
     
     
         13 . The method of  claim 2 , wherein the disease includes undesired angiogenesis that occurs due to contact lens overwear.  
     
     
         14 . The method of  claim 2 , wherein the disease includes undesired angiogenesis that occurs in atopic keratitis.  
     
     
         15 . The method of  claim 2 , wherein the disease includes undesired angiogenesis that occurs in superior limbic keratitis.  
     
     
         16 . The method of  claim 2 , wherein the disease includes undesired angiogenesis that occurs in pterygium keratitis sicca.  
     
     
         17 . The method of  claim 2 , wherein the disease includes undesired angiogenesis that occurs in sjogrens disease.  
     
     
         18 . The method of  claim 2 , wherein the disease includes undesired angiogenesis that occurs in rosacea.  
     
     
         19 . The method of  claim 2 , wherein the disease includes undesired angiogenesis that occurs in phylectenulosis.  
     
     
         20 . The method of  claim 2 , wherein the disease includes undesired angiogenesis that occurs in syphilis.  
     
     
         21 . The method of  claim 2 , wherein the disease includes undesired angiogenesis that occurs in Mycobacteria infections other than leprosy.  
     
     
         22 . The method of  claim 2 , wherein the disease includes undesired angiogenesis that occurs in lipid degeneration.  
     
     
         23 . The method of  claim 2 , wherein the disease includes undesired angiogenesis that occurs in chemical bums.  
     
     
         24 . The method of  claim 2 , wherein the disease includes undesired angiogenesis that occurs in bacterial ulcers.  
     
     
         25 . The method of  claim 2 , wherein the disease includes undesired angiogenesis that occurs in fungal ulcers.  
     
     
         26 . The method of  claim 2 , wherein the disease includes undesired angiogenesis that occurs in Herpes simplex infections.  
     
     
         27 . The method of  claim 2 , wherein the disease includes undesired angiogenesis that occurs in Herpes zoster infections.  
     
     
         28 . The method of  claim 2 , wherein the disease includes undesired angiogenesis that occurs in protozoan infections.  
     
     
         29 . The method of  claim 2 , wherein the disease includes undesired angiogenesis that occurs in Kaposi's sarcoma.  
     
     
         30 . The method of  claim 2 , wherein the disease includes undesired angiogenesis occurs in Mooren's ulcer.  
     
     
         31 . The method of  claim 2 , wherein the disease includes undesired angiogenesis that occurs in Terrien's marginal degeneration.  
     
     
         32 . The method of  claim 2 , wherein the disease includes undesired angiogenesis that occurs in marginal keratolysis.  
     
     
         33 . The method of  claim 2 , wherein the disease includes undesired angiogenesis caused by trauma.  
     
     
         34 . The method of  claim 2 , wherein the disease includes undesired angiogenesis that occurs in rheumatoid arthritis.  
     
     
         35 . The method of  claim 2 , wherein the disease includes undesired angiogenesis that occurs in systemic lupus.  
     
     
         36 . The method of  claim 2 , wherein the disease includes undesired angiogenesis that occurs in polyarteritis.  
     
     
         37 . The method of  claim 2 , wherein the disease includes undesired angiogenesis that occurs in Wegener's sarcoidosis.  
     
     
         38 . The method of  claim 2 , wherein the disease includes undesired angiogenesis that occurs in scleritis.  
     
     
         39 . The method of  claim 2 , wherein the disease includes undesired angiogenesis that occurs in Stevens-Johnson's disease.  
     
     
         40 . The method of  claim 2 , wherein the disease includes undesired angiogenesis that occurs in radial keratotomy.  
     
     
         41 . The method of  claim 2 , wherein the disease includes undesired angiogenesis that occurs in sickle cell anemia.  
     
     
         42 . The method of  claim 2 , wherein the disease includes undesired angiogenesis that occurs in sarcoidosis.  
     
     
         43 . The method of  claim 2 , wherein the disease includes undesired angiogenesis that occurs in pseudoxanthoma elasticum.  
     
     
         44 . The method of  claim 2 , wherein the disease includes undesired angiogenesis that occurs in Paget's disease.  
     
     
         45 . The method of  claim 2 , wherein the disease includes undesired angiogenesis that occurs in vein occlusion.  
     
     
         46 . The method of  claim 2 , wherein the disease includes undesired angiogenesis that occurs in artery occlusion.  
     
     
         47 . The method of  claim 2 , wherein the disease includes undesired angiogenesis that occurs in carotid obstructive disease.  
     
     
         48 . The method of  claim 2 , wherein the disease includes undesired angiogenesis that occurs in chronic uveitis.  
     
     
         49 . The method of  claim 2 , wherein the disease includes undesired angiogenesis that occurs in chronic vitritis.  
     
     
         50 . The method of  claim 2 , wherein the disease includes undesired angiogenesis that occurs in lyme's disease.  
     
     
         51 . The method of  claim 2 , wherein the disease includes undesired angiogenesis that occurs in Eales' disease.  
     
     
         52 . The method of  claim 2 , wherein the disease includes undesired angiogenesis that occurs in Behcet's disease.  
     
     
         53 . The method of  claim 2 , wherein the disease includes undesired angiogenesis that occurs in myopia.  
     
     
         54 . The method of  claim 2 , wherein the disease includes undesired angiogenesis that occurs in optic pits.  
     
     
         55 . The method of  claim 2 , wherein the disease includes undesired angiogenesis that occurs in Stargardt's disease.  
     
     
         56 . The method of  claim 2 , wherein the disease includes undesired angiogenesis that occurs in pars planitis.  
     
     
         57 . The method of  claim 2 , wherein the disease includes undesired angiogenesis that occurs in chronic retinal detachment.  
     
     
         58 . The method of  claim 2 , wherein the disease includes undesired angiogenesis that occurs in hyperviscosity syndromes.  
     
     
         59 . The method of  claim 2 , wherein the disease includes undesired angiogenesis that occurs in toxoplasmosis.  
     
     
         60 . The method of  claim 2 , wherein the disease includes undesired angiogenesis that occurs in post-laser complications.  
     
     
         61 . The method of  claim 2 , wherein the disease includes undesired angiogenesis that occurs in abnormal proliferation of fibrovascular tissue.  
     
     
         62 . The method of  claim 2 , wherein the disease includes undesired angiogenesis that occurs in hemangiomas.  
     
     
         63 . The method of  claim 2 , wherein the disease includes undesired angiogenesis that occurs in Osler-Weber- Rendu disease.  
     
     
         64 . The method of  claim 2 , wherein the disease includes undesired angiogenesis that occurs in solid tumors.  
     
     
         65 . The method of  claim 2 , wherein the disease includes undesired angiogenesis that occurs in blood borne tumors.  
     
     
         66 . The method of  claim 2 , wherein the disease includes undesired angiogenesis that occurs in acquired immune deficiency syndrome.  
     
     
         67 . The method of  claim 2 , wherein the disease includes undesired angiogenesis that occurs in ocular neovascular disease.  
     
     
         68 . The method of  claim 2 , wherein the disease includes undesired angiogenesis that occurs in osteoarthritis.  
     
     
         69 . The method of  claim 2 , wherein the disease includes undesired angiogenesis that occurs in diseases caused by chronic inflammation.  
     
     
         70 . The method of  claim 2 , wherein the disease includes undesired angiogenesis that occurs in Crohn's disease.  
     
     
         71 . The method of  claim 2 , wherein the disease includes undesired angiogenesis that occurs in ulcerative colitis.  
     
     
         72 . The method of  claim 2 , wherein the disease includes undesired angiogenesis that occurs in the tumors of rhabdomyosarcoma.  
     
     
         73 . The method of  claim 2 , wherein the disease includes undesired angiogenesis that occurs in the tumors of retinoblastoma.  
     
     
         74 . The method of  claim 2 , wherein the disease includes undesired angiogenesis that occurs in the tumors of Ewing's sarcoma.  
     
     
         75 . The method of  claim 2 , wherein the disease includes undesired angiogenesis that occurs in the tumors of neuroblastoma.  
     
     
         76 . The method of  claim 2 , wherein the disease includes undesired angiogenesis that occurs in the tumors of osteosarcoma.  
     
     
         77 . The method of  claim 2 , wherein the disease includes undesired angiogenesis that occurs in leukemia.  
     
     
         78 . The method of  claim 2 , wherein the disease includes undesired angiogenesis that occurs in psoriasis.  
     
     
         79 . The method of  claim 2 , wherein the disease includes undesired angiogenesis that occurs in atherosclerosis.  
     
     
         80 . The method of  claim 2 , wherein the disease includes undesired angiogenesis that occurs in pemphigoid.

Join the waitlist — get patent alerts

Track US2002049231A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.